Moneycontrol PRO
UPCOMING EVENT:Watch India’s Best Managed Companies 2021, Deloitte’s global marquee programme for private companies on 17th Sept, 12 pm. Register Now!

Five pharma cos get permission to produce antifungal drug Amphotericin B liposomal injection

The five companies that got permission to manufacture are Natco Pharma, Gufic Biosciences, Alembic Pharmaceuticals, Emcure Pharmaceuticals and Lyca Pharmaceuticals.

May 20, 2021 / 09:35 PM IST
Source: AFP

Source: AFP

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

The Drug Controller General of India (DCGI) has approved application of five companies to begin production of antifungal drug Amphotericin B liposomal injection, which is critical in the treatment of Mucormycosis, also called 'Black Fungus'.

The five companies that got permission to manufacture are Natco Pharma, Gufic Biosciences, Alembic Pharmaceuticals, Emcure Pharmaceuticals and Lyca Pharmaceuticals.

Currently six companies are manufacturing the drug these include Mylan, Bharat Serums and Vaccines, BDR Pharma, Sun Pharma, Cipla and Life Care.

"The existing pharma companies have already started ramping up the production.

Indian Companies have also placed orders for importing 6 lakh vials of AmphotericinB," said Minister of State for Chemicals and Fertilisers Mansukh Mandaviya.

Close

"We are leaving no stone unturned to smoothen the situation," Mandaviya said.

Please read here how the companies are scrambling to expand capacities.
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: May 20, 2021 09:35 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark